BioScrip, Inc.
Proforma Classification of Historical Segments – Year Ended December 31, 2008
		Q1			Q2			Q3			Q4			2008
Results of Operations:
Revenue:
Infusion/Home Health Services	$	30,539		$	33,499		$	33,299		$	34,491		$	131,828
Pharmacy Services		296,932			314,941			326,128			332,082			1,270,083
Total	$	327,471		$	348,440		$	359,427		$	366,573		$	1,401,911
Adjusted EBITDA by Segment before corporate overhead:
Infusion/Home Health Services	$	1,432		$	1,959		$	2,227		$	4,444		$	10,062
Pharmacy Services		7,766			11,018			9,826			8,667			37,277
Total Segment Adjusted EBITDA		9,198			12,977			12,053			13,111			47,339
Corporate overhead		(6,504	)		(7,057	)		(5,965	)		(6,470	)		(25,996	)
	$	2,694		$	5,920		$	6,088		$	6,641		$	21,343
Interest expense, net		(585	)		(677	)		(669	)		(780	)		(2,711	)
Income tax (expense) benefit		(77	)		(1,072	)		(730	)		14,075			12,196
Depreciation		(1,068	)		(1,030	)		(1,136	)		(1,223	)		(4,457	)
Amortization		(484	)		(484	)		(484	)		(484	)		(1,936	)
Stock-based compensation expense		(957	)		(1,038	)		(864	)		(931	)		(3,790	)
Transaction related expenses		-			-			-			-			-
Goodwill and intangible impairment		-			-			-			(93,882	)		(93,882	)
OIG settlement		-			-			(795	)		-			(795	)
Net income (loss):	$	(477	)	$	1,619		$	1,410		$	(76,584	)	$	(74,032	)
Depreciation Expense:
Infusion/Home Health Services		217			223		$	267			253		$	960
Pharmacy Services		612			565			587			669			2,433
Corporate unallocated		239			242			282			301			1,064
Total	$	1,068		$	1,030		$	1,136		$	1,223		$	4,457

1

BioScrip, Inc.
Proforma Classification of Historical Segments – Year Ended December 31, 2009
		Q1			Q2			Q3			Q4			2009
Results of Operations:
Revenue:
Infusion/Home Health Services	$	34,403		$	36,401		$	36,809		$	40,607		$	148,220
Pharmacy Services		291,346			292,348			296,667			300,944			1,181,305
Total	$	325,749		$	328,749		$	333,476		$	341,551		$	1,329,525
Adjusted EBITDA by Segment before corporate overhead:
Infusion/Home Health Services	$	2,172		$	2,662		$	2,586		$	3,222		$	10,642
Pharmacy Services		9,960			11,335			13,224			11,236			45,755
Total Segment Adjusted EBITDA		12,132			13,997			15,810			14,458			56,397
Corporate overhead		(5,962	)		(6,972	)		(7,793	)		(9,978	)		(30,705	)
	$	6,170		$	7,025		$	8,017		$	4,480		$	25,692
Interest expense, net		(594	)		(430	)		(447	)		(449	)		(1,920	)
Income tax (expense) benefit		(404	)		(377	)		(467	)		41,801			40,553
Depreciation		(1,111	)		(1,129	)		(1,356	)		(1,437	)		(5,033	)
Amortization		-			-			-			-			-
Stock-based compensation expense		(776	)		(712	)		(897	)		(1,034	)		(3,419	)
Transaction related expenses		-			-			-			(1,774	)		(1,774	)
Goodwill and intangible impairment		-			-			-			-			-
OIG settlement		-			-			-			-			-
Net income (loss):	$	3,285		$	4,377		$	4,850		$	41,587		$	54,099
Depreciation Expense:
Infusion/Home Health Services		325			302		$	277			281		$	1,185
Pharmacy Services		511			581			858			902			2,852
Corporate unallocated		275			246			221			254			996
Total	$	1,111		$	1,129		$	1,356		$	1,437		$	5,033

2